VolitionRx Limited (VNRX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by VolitionRx Limited on September 2, 2026. The filing reports on a material definitive agreement involving a waiver and consent granted by the Company's lender, Lind Global Asset Management XII LLC ("Lind"), regarding the Company's At-The-Market (ATM) equity sales program.
Key Financial Metrics and Debt Structure
The filing details the Company's existing debt obligations under a Securities Purchase Agreement with Lind:
- 2025 Note: Senior secured convertible promissory note with an original principal amount of $7,500,000 issued on May 15, 2025.
- 2026 Note: Senior secured convertible promissory note with an original principal amount of $2,400,000 issued on January 7, 2026.
- Warrants: Includes the 2025 Warrant (exercisable for up to 651,042 shares) and a warrant issued on January 7, 2026 (exercisable for up to 350,018 shares).
- ATM Agreement Limit: Previously capped at $10 million in Permitted ATM Sales per calendar year.
The filing does not provide current revenue, profit, cash flow, or liquidity metrics.
Material Changes and Agreement Details
On September 2, 2026, the Company and Lind entered into a Waiver and Consent with the following material effects:
- ATM Sales Cap Removal: Lind consented to ATM sales in excess of the $10 million annual limit, classifying them as Permitted ATM Sales rather than Prohibited Transactions.
- Waiver of Remedies: Lind waived remedies related to the Prohibited Transactions covenant and Event of Default provisions triggered by ATM sales. This includes waiving rights to accelerate debt, demand immediate payment, or foreclose on collateral due to these sales.
- Price Adjustments: The Waiver prevents future adjustments to the Conversion Price of the Notes and Exercise Price of the Warrants for ATM sales occurring after August 28, 2026. Adjustments for sales through August 28, 2026, were already applied.
Outlook, Risks, and Management Commentary
The filing indicates that the Company has secured flexibility to raise capital through its ATM program without triggering default events under its existing credit facility. The primary risk mitigated by this filing is the potential acceleration of debt obligations due to equity sales exceeding the previous $10 million threshold. No specific forward-looking guidance or management commentary regarding future financial performance is included in this document.
Key Facts for Investor Verification
- Verify the total amount of capital raised under the ATM program since August 28, 2026, to assess dilution impact.
- Confirm the current outstanding principal balance of the $7.5 million and $2.4 million notes.
- Review the updated Conversion Price of the Notes and Exercise Price of the Warrants following the August 28, 2026, adjustment.
- Check subsequent filings for any new covenants or restrictions imposed on the ATM program in exchange for this waiver.